Body Fluid Analysis for Cellular Composition; Approved Guideline

This guideline provides users with recommendations for collection and transport of body fluids, numeration and identification of cellular components, and guidance for qualitative and quantitative assessment of body fluid.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Clinical and Laboratory Standards Institute

Advancing Quality in Healthcare Testing

Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the healthcare community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related healthcare issues. Our process is based on the principle that consensus is an effective and cost-effective way to improve patient testing and healthcare services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, we provide an open and unbiased forum to address critical issues affecting the quality of patient testing and healthcare.

PUBLICATIONS

A document is published as a standard, guideline, or committee report.

Standard A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

Guideline A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

Report A document that has not been subjected to consensus review and is released by the Board of Directors.

CONSENSUS PROCESS

The CLSI voluntary consensus process is a protocol establishing formal criteria for:

- the authorization of a project
- the development and open review of documents
- the revision of documents in response to comments by users
- the acceptance of a document as a consensus standard or guideline.

Most documents are subject to two levels of consensus—“proposed” and “approved.” Depending on the need for field evaluation or data collection, documents may also be made available for review at an intermediate consensus level.

Proposed A consensus document undergoes the first stage of review by the healthcare community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

Approved An approved standard or guideline has achieved consensus within the healthcare community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (i.e., that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

Our standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following CLSI’s established consensus procedures. Provisions in CLSI standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are responded to by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any document. Address comments to Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

VOLUNTEER PARTICIPATION

Healthcare professionals in all specialties are urged to volunteer for participation in CLSI projects. Please contact us at customerservice@clsi.org or +610.688.0100 for additional information on committee participation.
Abstract

Clinical and Laboratory Standards Institute document H56-A—Body Fluid Analysis for Cellular Composition; Approved Guideline provides recommendations for standardizing the collection and transport of body fluids, numeration and identification of cellular components, and guidance for qualitative and quantitative assessment of body fluid.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the healthcare community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI/NCCLS documents. Current editions are listed in the CLSI catalog, which is distributed to member organizations, and to nonmembers on request. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org
Committee Membership

Area Committee on Hematology

Bruce H. Davis, MD
Chairholder
Maine Medical Center Research Institute
Scarborough, Maine

Samuel J. Machin, MB, ChB, FRCPath
Vice-Chairholder
The University College London Hospitals
London, United Kingdom

Dorothy M. Adcock, MD
Esoterix Coagulation
Aurora, Colorado

Frank M. LaDuca, PhD
Bayer HealthCare Diagnostics Division
Tarrytown, New York

Diane I. Szamosi, MA, MT(ASCP)SH
Chairholder
Greiner Bio-One North America, Preanalytics
Monroe, North Carolina

Josephine M. Bautista, MS, MT(ASCP)
FDA Center for Devices and Radiological Health
Rockville, Maryland

Joanne Cornbleet, MD, PhD
Stanford University Medical Center
Stanford, California

Lewis Glasser, MD
Rhode Island Hospital
Brown Medical School
Providence, Rhode Island

Maryalice Stetler-Stevenson, MD, PhD
National Institutes of Health Bethesda, Maryland

Charles F. Arkin, MD
Lahey Clinic
Burlington, Massachusetts

J. David Bessman, MD
University of Texas Medical Branch Galveston, Texas

Douglas J. Christie, PhD, FAHA
Dade Behring, Inc.
Newark, Delaware

Ian A. Giles, MD
Sysmex America, Inc.
Mundelein, Illinois

Jan W. Gratama, MD
Erasmus University Medical Center-Daniel Den Hoed Rotterdam, Netherlands

Mary Jo A. Koepke, MD
Durham, North Carolina

Francis Lacombe, MD, PhD
Laboratoire d’Hematologie Pessac, France

Kandice Kottke-Marchant, MD, PhD
The Cleveland Clinic Foundation Cleveland, Ohio

Richard A. Marlar, PhD
Oklahoma City VA Medical Center
Oklahoma City, Oklahoma

Powers Peterson, MD
Weill Cornell Medical College in Qatar
Doha, Qatar

Diane I. Szamosi, MA, MT(ASCP)SH
Greiner Bio-One North America, Preanalytics
Monroe, North Carolina

Gregor Rothe, DrMed
Bremer Zentrum für Laboratoriumsmedizin
Bremen, Germany

Linda Sandhaus, MD
University Hospitals of Cleveland
Cleveland, Ohio

Marc E. Key, PhD
Ojai, California

Aurelia M. Meloni-Ehrig, PhD, DSc
Quest Diagnostics, Nichols Institute
Chantilly, Virginia

Subcommittee on Body Fluid Analysis for Cellular Composition

Diane I. Szamosi, MA, MT(ASCP)SH
Chairholder
Greiner Bio-One North America, Preanalytics
Monroe, North Carolina

Josephine M. Bautista, MS, MT(ASCP)
FDA Center for Devices and Radiological Health
Rockville, Maryland

Joanne Cornbleet, MD, PhD
Stanford University Medical Center
Stanford, California

Lewis Glasser, MD
Rhode Island Hospital
Brown Medical School
Providence, Rhode Island

Gregor Rothe, DrMed
Bremer Zentrum für Laboratoriumsmedizin
Bremen, Germany

Linda Sandhaus, MD
University Hospitals of Cleveland
Cleveland, Ohio

Marc E. Key, PhD
Ojai, California

Aurelia M. Meloni-Ehrig, PhD, DSc
Quest Diagnostics, Nichols Institute
Chantilly, Virginia

Staff
Clinical and Laboratory Standards Institute
Wayne, Pennsylvania

John J. Zlockie, MBA
Vice President, Standards

David E. Sterry, MT(ASCP)
Staff Liaison

Donna M. Wilhelm
Editor

Melissa A. Lewis
Assistant Editor
Acknowledgement

This guideline was prepared by Clinical and Laboratory Standards Institute (CLSI), as part of a cooperative effort with IFCC to work toward the advancement and dissemination of laboratory standards on a worldwide basis. CLSI gratefully acknowledges the participation of IFCC in this project. The IFCC expert for this project is Gregor Rothe, DrMed, Bremer Zentrum für Laboratoriumsmedizin.

CLSI and the Subcommittee on Body Fluid Analysis for Cellular Composition gratefully acknowledge the following volunteers for their important contributions to the development and/or completion of this document: Marc E. Key, PhD; Aurelia M. Meloni-Ehrig, PhD, DSc, Quest Diagnostics; Naomi B. Culp, DA, MT(ASCP)SH, Beckman Coulter; William M. Dougherty, Iris Diagnostics; and Ian A. Giles, MD and Krista Curcio, Sysmex America, Inc.
Contents

Abstract.................................................................................................................................................... i
Committee Membership................................................................................................................................ iii
Foreword...................................................................................................................................................... vii

1 Scope...................................................................................................................................................... 1

2 Standard Precautions............................................................................................................................... 1

3 Definitions ............................................................................................................................................... 1

4 Preanalytical Variables ........................................................................................................................... 3

5 Specimen Collection .................................................................................................................................. 5
  5.1 Cerebrospinal Fluid .................................................................................................................................... 5
  5.2 Serous Fluid ............................................................................................................................................. 5
  5.3 Synovial Fluid ......................................................................................................................................... 6
  5.4 Bronchoalveolar Lavage (BAL) ............................................................................................................. 7

6 Specimen Handling and Transport........................................................................................................... 7
  6.1 CSF ........................................................................................................................................................ 7
  6.2 Serous Fluids ......................................................................................................................................... 7
  6.3 Synovial Fluids ...................................................................................................................................... 8
  6.4 BAL ....................................................................................................................................................... 8

7 Quantitative Assessment........................................................................................................................... 8
  7.1 Manual Counting ..................................................................................................................................... 8
  7.2 Automated Methods ............................................................................................................................... 11

8 Morphology Assessment .......................................................................................................................... 14
  8.1 Slide Preparation .................................................................................................................................... 14
  8.2 Identification of Morphologic Constituents .......................................................................................... 16
  8.3 Evaluation of Nucleated Cell Subtypes ................................................................................................ 26
  8.4 Physician Review .................................................................................................................................. 26
  8.5 Result Reporting ................................................................................................................................... 27

9 Fluid Types .............................................................................................................................................. 27
  9.1 Cerebrospinal Fluid and Ventricular Shunt Fluids .............................................................................. 27
  9.2 Serous (Pleural, Peritoneal, Pericardial, Peritoneal Lavage and Dialysate Fluids)........................... 30
  9.3 Synovial Fluid ....................................................................................................................................... 35
  9.4 Bronchoalveolar Lavage Fluid .......................................................................................................... 41

10 Additional Studies .................................................................................................................................. 44
  10.1 Immunocytologic Studies .................................................................................................................. 44
  10.2 Flow Cytometric Studies .................................................................................................................. 52
  10.3 Cytogenetic Analysis ......................................................................................................................... 57

11 Sample Storage After Completion of Testing....................................................................................... 57
Contents (Continued)

12 Quality Control and Quality Assurance .................................................................57
  12.1 Quality Control ...............................................................................................57
  12.2 Quality Assurance ..........................................................................................58
  12.3 Proficiency Testing (External Quality Assessment) ...........................................59
  12.4 Continuous Education and Training ..............................................................59
References .................................................................................................................60
Additional References ...............................................................................................65
Appendix A. Reagent Formulations .........................................................................66
Appendix B. Interpretation of Cell Types .................................................................67
Appendix C. Reference Intervals ..............................................................................70
Summary of Comments and Subcommittee Responses ............................................74
The Quality System Approach ................................................................................96
Related CLSI/NCCLS Publications .........................................................................97
Foreword

Clinical data derived from proper body fluid procedures and accurate test results are essential to make the appropriate diagnosis and administer the proper therapy to patients. Some variables may influence the test results reported. Because these variables are loosely defined, inconsistency from one institution to another may exist. This guideline will provide users with recommendations for the collection and transport of body fluids, procedures for the numeration and identification of cellular components, and guidelines for the qualitative and quantitative assessment of body fluids.

A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, ISO, and CEN documents; and that legally required use of terms, regional usage, and different consensus timelines are all challenges to harmonization. Despite these challenges, CLSI recognizes that harmonization of terms facilitates the global application of standards and is an area that needs immediate attention. Implementation of this policy must be an evolutionary and educational process that begins with new projects and revisions of existing documents.

Key Words

Body fluids, bronchoalveolar lavage, cerebrospinal fluid, pericardial fluid, peritoneal fluid, pleural fluid, serous fluid, synovial fluid
Body Fluid Analysis for Cellular Composition; Approved Guideline

1 Scope

The intended purpose of this guideline is to explain how to collect, process, examine, store, and report results for body fluid specimens for the characterization of inflammatory, infectious, neoplastic, and immune alterations. It will also discuss preanalytical, analytical, and postanalytical variables related to body fluid cellular analyses. For the purpose of this document, the following body fluids will be discussed: cerebrospinal, serous (pleural, peritoneal, pericardial) and related fluids (i.e., peritoneal dialysate, peritoneal lavage), bronchoalveolar, and synovial fluids.

This guideline describes manual and automated methods to enumerate cellular components and to identify normal and abnormal elements. It also addresses additional studies that may be used for body fluid testing in the routine clinical laboratory.

This document is intended for medical technologists, pathologists, microbiologists, cytologists, nurses, and other healthcare professionals responsible for the collection and transport of body fluid specimens to the clinical laboratory, as well as the processing, testing, and reporting of results. It is also intended for manufacturers of products or instruments used for body fluid testing.

2 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the U.S. Centers for Disease Control and Prevention (Garner JS, Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol. 1996;17(1):53-80). For specific precautions for preventing the laboratory transmission of all infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all infectious disease, refer to the most current edition of CLSI document M29—Protection of Laboratory Workers From Occupationally Acquired Infections.

3 Definitions

accuracy (of measurement) – closeness of the agreement between the result of a measurement and a true value of the measurand (VIM93).1

analytical sensitivity – in quantitative testing, the change in response of a measuring system or instrument divided by the corresponding change in the stimulus (modified from VIM93); NOTE 1: The sensitivity may depend on the value of the stimulus; NOTE 2: The sensitivity depends on the imprecision of the measurements of the sample; NOTE 3: In qualitative testing, the test method’s ability to obtain positive results in concordance with positive results obtained by the reference method; NOTE 4: If the true sensitivity of a device is better than the reference method, its apparent specificity will be less and the level of apparent false-positive results will be greater; NOTE 5: For FISH, the percentage of scorable nuclei or metaphase cells with the expected signal pattern (number of signals, size of signals, and color of signals).